Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.

Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.

Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.

Abstract: The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFN?”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFN? protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFN? subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFN? related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.

Abstract: The present invention includes compositions and methods for the isolation, purification and preparation of immunogenic antigens for the production of customized cancer vaccines that include dendritic cells that are contacted with an antigen that includes heat-shocked cancer cells.

Abstract: Porphyromanas gingivalis LPS elicits a Th2 immune response. P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, or mimetics thereof, can be used as adjuvants to elicit a Th2 immune response, increase the efficacy of vaccinations in infectious diseases, decrease the severity of autoimmune responses, boost the Th2 immune response when needed in combination with the Th1 immune response, facilitate the industrial production of antibodies when used in animals, and study the Th2 immune response in laboratory animal research.

Abstract: A method of treating malignancies through induction of immune responses has been found. In one aspect, the present invention is a method for treating malignancy comprising administering an effective amount of a vaccine comprising antigen-presenting cells loaded with at least two or more agents selected from the group consisting of tumor antigens and tumor antigen derived peptides. In another embodiment, the vaccine comprises at least two or more agents selected from the group consisting of tumor antigens and tumor antigen derived peptides which target antigen-presenting cells in the patient. The vaccines can also further comprise antigen-presenting cells loaded with control antigens used to determine the patient's immune competence. The evaluation of vaccine-induced immune responses in blood provides a predictive factor for treatment efficacy.

Abstract: Porphyromanas gingivalis LPS elicits a Th2 immune response. P. gingivalis LPS, detoxified P. gingivalis LPS, derivatives of P. gingivalis LPS, derivatives of detoxified P. gingivalis LPS, P. gingivalis Lipid A, detoxified P. gingivalis Lipid A, derivatives of P. gingivalis Lipid A, derivatives of detoxified P. gingivalis Lipid A, or mimetics thereof, can be used as adjuvants to elicit a Th2 immune response, increase the efficacy of vaccinations in infectious diseases, decrease the severity of autoimmune responses, boost the Th2 immune response when needed in combination with the Th1 immune response, facilitate the industrial production of antibodies when used in animals, and study the Th2 immune response in laboratory research.

Abstract: The invention provides a method for treating an autoimmune disease in a subject by administering an interferon antagonist and a Flt3 ligand (Flt3L) antagonist. The invention also provides compositions containing one or more interferon antagonists, and one or more Flt3L antagonists, an in vitro assay for determining a subject's risk for developing an autoimmune disease, and kits for use, inter alia, with the assay.

Abstract: The present invention relates to compositions and methods for producing antigen-presenting cells, in vitro, ex vivo or in vivo. This invention relates more particularly to methods and compositions for producing dendritic cells using interleukin-15, preferably in combination with a growth factor such as Granulocyte-Macrophage colony stimulating factor. This invention is particularly suited for producing immature dendritic cells and activated cells from precursors, in vitro, ex vivo or in vivo. The invention also relates to compositions for implementing these methods, as well as compositions comprising antigen-presenting cells and uses thereof. Dendritic cells or membrune vesicles derived therefrom have utility in many applications, including diagnostic, therapy, vaccination, research, screening and gene delivery.

Abstract: The invention provides a method for treating an autoimmune disease in a subject by administerineng an interfron antagonist and Flt3 ligand (Flt3L) antagonist. The invention also provides compositions containing one or more interferon antagonists, and one or more Flt3L antagonists, an in vitro assay for determining a subject's risk for developing an autoimmune disease, and kits for use, inter alia, with the assay.

Abstract: The present invention relates to a monoclonal antibody-and to the hybridoma that produces it-specific for a surface antigen of activated B cells and T cells transformed by the virus HTLV-I. The hybridoma has been deposited with the European Collection of Annimal Cell Cultures (ECACC) under the number 88062301.